Unveiling the role of circulating periostin in patients with idiopathic pulmonary fibrosis: A prognostic meta-analysis

Wasfi Alghwyeen; Shrouk F. Mohamed; Ahmed Shamil Hashim; Abdelrahman M.  Tawfik; Ahmed  Kertam

doi:10.36141/svdld.v42i4.16980

Authors

Wasfi Alghwyeen Department of Internal Medicine, Istishari Hospital, Amman, Jordan
Shrouk F. Mohamed Faculty of Medicine, Alexandria University, Alexandria, Egypt
Ahmed Shamil Hashim College of Medicine, University of Baghdad, Iraq
Abdelrahman M. Tawfik Faculty of Medicine, Alexandria University, Alexandria, Egypt
Ahmed Kertam Faculty of Medicine, Ain-Shams University, Cairo, Egypt

Keywords:

IPF, meta-analysis, periostin

Abstract

Background: Periostin measurement has been suggested as a noninvasive biomarker for assessing the likelihood of IPF progression and predicting patient outcomes, but these results aren't entirely consistent. Therefore, we conducted a meta-analysis to study the relation between serum periostin and IPF.

Methods: We conducted a comprehensive search in major electronic biomedical databases of (PubMed, Scopus, Cochrane Library, EMBASE and Web of Science) spanning from inception to September 2024. Meta-analysis of included studies was done, and quantitative data were pooled as standardized mean difference (SMD), odd rations (ORs) and coefficient (r) values , with corresponding 95% confidence intervals (CIs).

Results: Eleven articles were included in final meta-analysis. Our results showed that there was no significant difference in periostin levels between IPF patients and healthy controls (SMD: 2.59, 95% CI: -0.59 to 5.77, p= 0.11). Moreover, it was shown that IPF patients with a progressive disease have higher periostin levels compared to those who remain stable (SMD: 0.52, 95% CI: 0.29 to 0.75, p<0.0001). In addition to, higher serum periostin levels were significantly associated with shortened overall survival among IPF patients (RR: 3.70, 95% CI: 1.84 to 7.43, p<0.0001). Finally, there was a significant negative correlation between periostin levels and relative decline in DLCO and VC over the follow-up period (COR: -0.36, 95% CI, -0.58 to -0.10), (COR: -0.49, 95% CI, -0.63 to -0.34) respectively.

Conclusions: This study concludes that periostin may be a valuable biomarker for predicting prognosis in IPF patients.

References

1. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976;85(6):769–88.

2. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–68.

3. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40.

4. Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(3):00019–2016.

5. White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2016;194(10):1242–51.

6. Sonnenberg-Riethmacher E, Miehe M, Riethmacher D. Periostin in allergy and inflammation. Front Immunol. 2021;12:722170.

7. Okamoto M, Izuhara K, Ohta S, Ono J, Hoshino T. Ability of periostin as a new biomarker of idiopathic pulmonary fibrosis. Adv Exp Med Biol. 2019;1132:79–87.

8. Izuhara K, Nunomura S, Nanri Y, et al. Periostin in inflammation and allergy. Cell Mol Life Sci. 2017;74(23):4293–303.

9. O’Dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017;74(23):4305–14.

10. Ohta S, Okamoto M, Fujimoto K, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One. 2017;12(3):e0174547.

11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

12. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.

13. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

14. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011;37(5):1119–27.

15. Naik PK, Bozyk PD, Bentley JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012;303(12):L1046–56.

16. Tajiri M, Okamoto M, Fujimoto K, et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Investig. 2015;53(2):73–81.

17. Yoshihara T, Nanri Y, Nunomura S, et al. Periostin plays a critical role in the cell cycle in lung fibroblasts. Respir Res. 2020 Dec;21(1):38.

18. Isshiki T, Matsuyama H, Yamaguchi T, Morita T, Ono J, Nunomura S, et al. Plasma matrix metalloproteinase 7, CC-chemokine ligand 18, and periostin as markers for pulmonary sarcoidosis. Respir Investig. 2020 Nov;58(6):479–87.

19. Izuhara K, Conway SJ, Moore BB, et al. Roles of Periostin in Respiratory Disorders. Am J Respir Crit Care Med. 2016 May 1;193(9):949–56.

20. Creamer AW, Barratt SL. Prognostic factors in chronic hypersensitivity pneumonitis. Eur Respir Rev. 2020 June 30;29(156):190167.

21. Matama G, Okamoto M, Fujimoto K, et al. Periostin Is a Biomarker of Rheumatoid Arthritis-Associated Interstitial Lung Disease. JCM. 2023 Nov 15;12(22):7100.

22. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016 Mar 4;17:23.

23. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008 Apr 29;5(4):e93.